Dr. Schayowitz has served as our Acting Chief Development Officer since October 2025. Dr. Schayowitz brings nearly 20 years of experience in oncology drug development to Zymeworks, having led dozens of global development programs from initiation through approval and commercialization. Prior to joining EcoR1 as an Operating Partner, he was a Vice President at Pfizer Oncology holding various development leadership roles across breast cancer, prostate cancer, colorectal cancer and melanoma, ultimately culminating in serving as Head of Product Development Teams. Prior to Pfizer, Dr. Schayowitz led the development of Zejula (niraparib) at Tesaro and was a member of the Medical Affairs leadership team at Algeta supporting the commercialization of Xofigo (Radium-223). He is currently a Board Member at Terremoto Biosciences and serves as a Board Observer for Aktis Oncology. Dr. Schayowitz has a BA from Hamilton College, a Ph.D. in Pharmacology from The University of Maryland, and an MBA from Johns Hopkins.

Dr. Moore joined Zymeworks in July 2022 and serves as our Chief Scientific Officer. Dr. Moore has more than 25 years of US-based experience in biologics drug discovery and development in biotechnology research. His career efforts have led to the discovery and development of a range of FDA-approved and clinical-stage biologics for patients with difficult-to-treat cancers and autoimmune conditions. Prior to joining Zymeworks, Dr. Moore served as Vice President, Cell Biology, and Immunology at MacroGenics from April 2008 to July 2022, leading a team of approximately 50 researchers engaged in the discovery, preclinical validation and clinical development of antibody-based therapeutics, including bispecific antibodies and antibody drug conjugates. Among the portfolio supported by Dr. Moore were FDA-approved Margenza (margetuximab-cmkb) for treatment of HER2+ breast cancer, Zynyz (retifanlimab-dlwr) for treatment of Merkel cell carcinoma and Tzield (teplizumab-mzwv) to delay onset of type I diabetes. Prior to joining MacroGenics, Dr. Moore was Director of Cell Biology at Celera from May 2005 to April 2008, where he oversaw research leveraging proteomic-based discoveries to validate novel cancer targets suitable for antibody-based therapeutics. Dr. Moore began his industrial career at Human Genome Sciences (HGS), holding several titles within research culminating in Director of Lead Product Development, where he managed various genomic-based target discovery programs including efforts that led to the discovery, development, approval, and commercialization of Benlysta (belimumab) for the treatment of systemic lupus erythematosus. Dr. Moore has an extensive research record co-authoring over 75 peer-reviewed manuscripts and is a named co-inventor on over 50 issued US patents. Dr. Moore holds a Ph.D. in Molecular Genetics from the University of Glasgow, performed post-doctoral work at the Roche Institute of Molecular Biology in Nutley, New Jersey, and also holds a degree in Biotechnology from the University of Strathclyde.

Mr. Hollywood joined Zymeworks in 2019 and currently serves as our Executive Vice President and Chief Operating Officer. Mr. Hollywood brings over 25 years of experience in the biopharmaceutical industry, most recently as Vice President and Head of ZymoGenetics (a Bristol-Myers Squibb company), where he oversaw biologics development, manufacturing, quality, and supply chain operations. He joined ZymoGenetics in 2010 and led technical operations for a portfolio of clinical and commercial products, and was responsible for building and managing a multi-host drug substance manufacturing facility. Mr. Hollywood brings a wealth of experience in operations management, having held positions of increasing responsibility in process science, manufacturing, quality, and regulatory compliance at organizations including Amgen, Dendreon and Centeon (a Rhone-Poulenc Rorer and Hoescht company). Mr. Hollywood has a Bachelor of Science degree in Biological Sciences from Western Illinois University.

Dr. Shang-Chiung (Charles) Chen joined Zymeworks in July 2022, bringing extensive experience in translational sciences and clinical pharmacology, with a strong focus on oncology and rare diseases. He currently serves as Vice President of Translational Sciences at Zymeworks, where he leads the Clinical Pharmacology, Pharmacometrics, Biomarker & Bioinformatics, Bioanalysis, and Toxicology functions.

Prior to joining Zymeworks, Dr. Chen built a distinguished track record of leading cross-functional teams and advancing new molecular entities from preclinical development through regulatory submission at leading pharmaceutical companies, including Genentech, Pfizer, and Travere Therapeutics. His clinical development expertise is underscored by key leadership roles in successful regulatory submissions such as KADCYLA and FILSPARI, as well as extensive interactions with global health authorities, including the FDA and EMA. He has broad experience across multiple therapeutic modalities, including antibody–drug conjugates (ADCs), T cell engagers (TCEs), immuno-oncology agents, and small molecules.

Dr. Chen received his Ph.D. in Molecular Pharmacology and Cancer Therapeutics from the State University of New York (SUNY) at Buffalo.

Ms. Desai joined Zymeworks in May 2020 and currently serves as the Senior Vice President, Finance. Ms. Desai brings more than 17 years of experience providing oversight of operational and strategic finance support in the customer service, technology, and life sciences industries. Prior to joining Zymeworks, Ms. Desai held a variety of R&D and Commercial FP&A and Corporate Strategy positions, starting with CTI BioPharma, Juno Therapeutics, and Alder BioPharmaceutical Inc. Ms. Desai holds her M.B.A. with a concentration in Finance from Texas A&M University, and is an active member of Healthcare Businesswomen’s Association (HBA) Seattle Chapter holding the position of Mentoring Chair.

Dr. Foulkes joined Zymeworks in January 2024, bringing over 25 years of experience in the biotechnology, biopharma and medical device industries. Prior to joining Zymeworks, Dr. Foulkes was Chief Operating Officer of Arecor, a UK AIM-listed, clinical-stage biopharmaceutical company. Joining at the point of IPO, she implemented organizational and operational changes to position the company for future growth. Dr. Foulkes has held senior commercial roles covering corporate and business development, marketing and clinical portfolio management, with a therapeutic focus on immunology, inflammation, oncology and rare diseases. She has worked for organizations including Liminal Biosciences (previously known as Prometic Life Sciences), Acambis, and Cangene Corporation, and she was part of the start-up team for the medical device company, Nexan Ltd. Dr. Foulkes started her commercial career in management consultancy with McKinsey & Company and during her career she has also worked as a freelance consultant providing business development, strategy and market analysis support within the biotechnology industry, with a focus on oncology and immunology companies. Dr. Foulkes holds a Ph.D. in Leukaemia Research and a B.Sc in Immunology, awarded by the University of Glasgow.

Ms. Graham joined Zymeworks in September 2018, and currently serves as our Vice President, Legal. Ms. Graham brings over 17 years of diverse legal experience to Zymeworks, having previously worked in private practice for over a decade at one of Canada’s largest law firms, and in-house with Avigilon Corporation (a Motorola Solutions company). Ms. Graham received a LL.B/J.D. from Queen’s University and a Bachelor of Arts from Concordia University. She is a member of the bar in British Columbia.

Ms. Inamdar joined Zymeworks in September 2023 and currently serves as Vice President, Investor Relations. She brings more than a decade of experience in investor relations, corporate communications, and strategic stakeholder engagement across the biotechnology and life sciences industries. In her current role, Ms. Inamdar leads the Company’s global investor relations strategy, oversees all investor-facing communications, and advises the Chief Executive Officer and Board of Directors on market positioning and key valuation drivers.

Prior to joining Zymeworks, Ms. Inamdar held senior roles at Liminal BioSciences, including Associate Director of Investor Relations and Communications, where she was responsible for investor engagement, financial communications, and ESG initiatives. Her professional background also includes advisory work with early-stage biotechnology companies, providing strategic counsel on investor relations, business development, and commercial strategy for organizations pursuing seed and venture capital financing. Earlier in her career, she held positions at Prometic BioSciences and Astrea BioSeparations, with a focus on digital strategy, marketing, and business development.

Ms. Inamdar holds post-graduate degrees in Public Relations, and Digital Marketing from the Chartered Institute of Public Relations, and The Institute of Direct and Digital Marketing respectively. She earned a BSc (Honours) in Psychology from the University of Westminster.

Dr. Mekan joined Zymeworks in April 2025 and serves as our Senior Vice President of Clinical Development. Dr. Mekan previously served as Executive Director, Global Development Lead for the lung and gastrointestinal cancer franchises with Gilead Sciences based in the U.S. Prior to Gilead, she was the Senior Medical Director, Oncology R&D at Daiichi Sankyo U.S. responsible as global clinical development lead for two antibody-drug conjugates. She began her pharmaceutical career as a Medical Director with Bristol-Myers Squibb with a focus on immune-oncology. Before joining the pharmaceutical industry, she served as an Assistant Professor at Hofstra North Shore LIJ School of Medicine and Attending Hematologist/Oncologist at North Shore Long Island Jewish Hospital in New York City. Dr. Mekan completed her residency in Internal Medicine at the University of Cincinnati, OH, and a fellowship in Hematology and Oncology at the Staten Island University Hospital of Northshore-LIJ Health System (now Northwell Health). She is board-certified in Internal Medicine, Oncology and Hematology and has authored numerous publications.

Ms. O’Connor joined Zymeworks in 2020 and currently serves as our Senior Vice President and Chief Human Resources Officer. Ms. O’Connor brings more than 20 years of experience within Human Resources, specializing in the pharmaceutical and biotech industry for over 13 years. Prior to joining Zymeworks, Ms. O’Connor held a variety of Human Resources leadership positions, starting with PointClickCare, Takeda Canada, Ferring Pharmaceuticals and most recently Merz Pharma. Ms. O’Connor holds a Bachelor of Arts degree in Psychology from the University of Waterloo and a certificate in Strategic Human Resources Management from the Rotman School of Business.

Ms. Papove joined Zymeworks in August 2020 and currently serves as Vice President, Corporate Communications. She brings more than a decade of experience supporting clinical- and commercial-stage biotechnology companies across strategic corporate communications and investor relations.

Prior to joining Zymeworks, Ms. Papove held communications and corporate affairs roles at biotechnology companies, including Sierra Oncology, where she partnered closely with executive leadership to support company building, corporate positioning, investor engagement, and cross-functional initiatives spanning R&D, medical affairs, and commercial readiness. Her experience includes working in high-growth, startup environments through periods of significant transformation, including rebranding, pipeline advancement, and strategic transactions.

Ms. Papove holds a Bachelor of Commerce from Royal Roads University.

Mr. Platshon has served as our Acting Chief Investment Officer since November 2025. Mr. Platshon has served as a Partner at EcoR1 Capital since December 2020. Mr. Platshon was also a Principal at EcoR1 Capital from December 2017 to December 2020, and has been with EcoR1 Capital since October 2015. Prior to joining EcoR1 Capital, Mr. Platshon served as an analyst at Aquilo Partners, a San Francisco life-sciences investment bank, from September 2014 to September 2015. Mr. Platshon has served on the board of directors of Kumquat Biosciences Inc. since February 2021 (prior to that he was a board observer since August 2019) and Ajax Therapeutics, Inc. since May 2021, and previously served on the board of directors of Terremoto Biosciences from October 2023 to December 2024. Mr. Platshon received his B.S. in Bioengineering from Stanford University.

Ms. Spencer joined Zymeworks in May 2025 and currently serves as the Vice President, Treasury and Tax. Ms. Spencer brings more than 23 years of experience in global tax planning and compliance coupled with extensive expertise in providing oversight of operational and strategic finance functions including tax, equity administration, treasury and insurance across the hospitality, technology, and life sciences industries. Prior to joining Zymeworks, Ms. Spencer held leadership positions in the life science industry at Revance Therapeutics and Dynavax Technologies. Ms. Spencer holds a Juris Doctorate with a concentration in Tax from William Mitchell College of Law and has been an active member of Healthcare Businesswomen’s Association (HBA) San Francisco Chapter.

Dr. Zheng joined Zymeworks in October 2024 and currently serves as our Vice President, Regulatory Affairs. He brings over 13 years of global regulatory experience to Zymeworks, having previously supported, led and overseen regulatory strategies and approvals for more than 20 development programs across all stages of product development. Before joining Zymeworks, Dr. Zheng headed up the Clinical Regulatory, Regulatory Operations and Quality System functions at NGM Biopharmaceuticals. Prior to NGM, He was a Global Regulatory Team Leader at Seagen Inc. He started his global regulatory career with Bayer. Dr. Zheng holds a Ph.D. in Interdisciplinary Biomedical Sciences from the Weldon School of Biomedical Engineering at Purdue University, as well as a Master of Science in Applied Statistics from Purdue University. He received his B.Sc. in Biochemistry from The Hong Kong University of Science and Technology. Dr. Zheng has held the Regulatory Affairs Certification (RAC-US) since 2011.